Cogentix Medical (CGNT) Receives News Sentiment Rating of 0.06
News headlines about Cogentix Medical (NASDAQ:CGNT) have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Cogentix Medical earned a news sentiment score of 0.06 on Accern’s scale. Accern also assigned news headlines about the medical device company an impact score of 45.9310369829346 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
These are some of the headlines that may have impacted Accern’s scoring:
- Allscripts’ Latest Initiative Eradicates Price Ambiguity (finance.yahoo.com)
- DaVita’s (DVA) Green Initiatives Win a Coveted Golden Reward (finance.yahoo.com)
- Critical Analysis: Cogentix Medical (CGNT) and Thermo Fisher Scientific (TMO) (americanbankingnews.com)
- Cogentix Medical Announces Cahaba GBA, LLC Extends Coverage for Urgent PC Maintenance Therapy (finance.yahoo.com)
Cogentix Medical (CGNT) opened at 2.94 on Tuesday. Cogentix Medical has a 52 week low of $1.37 and a 52 week high of $3.26. The stock has a 50 day moving average of $2.32 and a 200 day moving average of $1.91. The company’s market cap is $179.09 million.
Cogentix Medical (NASDAQ:CGNT) last released its quarterly earnings results on Tuesday, August 1st. The medical device company reported $0.01 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.01) by $0.02. The company had revenue of $14.06 million for the quarter, compared to analysts’ expectations of $13.90 million. Cogentix Medical had a negative return on equity of 13.83% and a negative net margin of 35.88%. Equities research analysts predict that Cogentix Medical will post ($0.03) earnings per share for the current fiscal year.
Separately, Zacks Investment Research raised shares of Cogentix Medical from a “sell” rating to a “hold” rating in a research note on Tuesday, July 4th.
TRADEMARK VIOLATION WARNING: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/09/19/cogentix-medical-cgnt-receives-news-sentiment-rating-of-0-06.html.
About Cogentix Medical
Cogentix Medical, Inc is a global medical device company. The Company designs, develops, manufactures and markets a line of fiber-optic and video endoscopy products under the PrimeSight brand that are used across various surgical specialties in diagnostic and treatment procedures. The Company also offers the Urgent PC Neuromodulation System (Urgent PC Systems), a device that delivers percutaneous tibial nerve stimulation (PTNS), for the office-based treatment of overactive bladder (OAB).
Receive News & Stock Ratings for Cogentix Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cogentix Medical Inc. and related stocks with our FREE daily email newsletter.